CHRDL2 Polyclonal Antibody, Biotin Conjugated
Applications
Reactivity
Predicted Reactivity
Overview | |
Catalog # | bs-3860R-Biotin |
Product Name | CHRDL2 Polyclonal Antibody, Biotin Conjugated |
Applications | WB, ELISA, IHC-P, IHC-F |
Reactivity | Mouse, Rat |
Predicted Reactivity | Human, Cow, Sheep |
Specifications | |
Conjugation | Biotin |
Host | Rabbit |
Source | KLH conjugated synthetic peptide derived from human CHRDL2 |
Immunogen Range | 351-429/429 |
Clonality | Polyclonal |
Isotype | IgG |
Concentration | 1ug/ul |
Purification | Purified by Protein A. |
Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Storage Condition | Store at -20°C for 12 months. |
Target | |
Gene ID | 25884 |
Subcellular location | Secreted |
Synonyms | BNF1; Breast tumor novel factor 1; CHL2; chordin like 2; Chordin like protein 2 precursor; Chordin related protein 2; CRDL2_HUMAN. |
Background | CHRDL2 is a novel chordin like protein that can act as a BMP antagonist. Amember of the chordin family of proteins, it contains a signal peptide andthree CR (cysteine-rich repeat) domains. When expressed as a recombinantprotein it is secreted and binds to activin A, but not to BMP-2, -4, -6. Differential expression has been detected in developing chondrocytes, myoblasts, osteoblasts, and osteoarthritic joints. Complex alternative splicing of CHRDL2 potentially results in distinct isoforms that differ at their C termini, in the expression of signal peptide, and in the content of CR domains. CHRDL2 was originally characterized as a novel protein exclusively expressed in breast, lung, and colon tumors. |
Application Dilution | |
WB | 1:300-5000 |
ELISA | 1:500-1000 |
IHC-P | 1:200-400 |
IHC-F | 1:100-500 |